Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients

Cell(2020)10.1016/j.cell.2020.09.044Source: DataRank Database

Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients is a research paper published in Cell (2020). On theSindex it has a DataRank of 0. It has been cited 249 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access249 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (15 grants)Impact (FWCI 10.74)OA: bronzeTopics (35)Linked Datasets (20)DataCite Reuse (20)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

Jenny Y. Xue ORCID,Piro Lito ORCID,Dong-Sung Kim ORCID

Live enrichment

PubMed:33065029 PMC:PMC7669705 OpenAlex:https://openalex.org/W3093242429

American Lung Association

Grant: T32GM007739

American Lung Association

Grant: F30CA232549

National Cancer Institute

Grant: 1R01CA23026701A1

National Cancer Institute

Grant: 1R01CA23074501

National Cancer Institute

Grant: K08CA191082-01A1

NCI NIH HHS

Grant: K08 CA191082

NCI NIH HHS

Grant: R01 CA230267

NCI NIH HHS

Grant: R01 CA230745

National Institutes of Health

Grant: 5K08CA191082-02

Elucidating the regulation of mitosis by BRAF V600E in lung cancer

National Institutes of Health

Grant: 5T32GM007739-30

Weill Cornell/Rockefeller/Sloan-Kettering MST Program

National Institutes of Health

Grant: 1F30CA232549-01

Dissecting the evolution of targeted therapy resistance in BRAFV600E-mutant cancer

Pew Charitable Trusts

Amgen

National Institutes of Health

Damon Runyon Cancer Research Foundation

FWCI

10.74

Citation Percentile

1.0%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

bronzeLicense: Elsevier Non-Commercial

journalhttp://www.cell.com/article/S0092867420312411/pdf

publisherhttp://www.cell.com/article/S0092867420312411/pdf

publisherhttps://api.elsevier.com/content/article/PII:S0092867420312411?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0092867420312411?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.cell.2020.09.044

Fields of Study

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK PathwaysCancer-related Molecular Pathways0301 basic medicine0303 health sciences03 medical and health sciencesAntineoplastic AgentsClinical Trials as TopicDrug Resistance, NeoplasmHumansMolecular Targeted TherapyMutationProto-Oncogene Proteins p21(ras)

MeSH Terms

Antineoplastic AgentsClinical Trials as TopicHumansMutationProto-Oncogene Proteins p21(ras)Drug Resistance, NeoplasmMolecular Targeted Therapy

Keywords

BiologyInhibitory postsynaptic potentialMechanism (biology)KRASCancer researchPharmacologyMutationNeuroscienceGeneticsProto-Oncogene Proteins p21(ras)Clinical Trials as TopicDrug Resistance, NeoplasmHumansAntineoplastic AgentsMolecular Targeted Therapy

Sustainable Development Goals

SDG 3: 3. Good health

Additional file 1 of Comprehensive analysis of m6A related gene mutation characteristics and prognosis in colorectal cancer

10.6084/m9.figshare.22877499.v1figshare

Additional file 1 of Comprehensive analysis of m6A related gene mutation characteristics and prognosis in colorectal cancer

10.6084/m9.figshare.22877499figshare

Additional file 2 of Comprehensive analysis of m6A related gene mutation characteristics and prognosis in colorectal cancer

10.6084/m9.figshare.22877505.v1figshare

Additional file 2 of Comprehensive analysis of m6A related gene mutation characteristics and prognosis in colorectal cancer

10.6084/m9.figshare.22877505figshare

Additional file 3 of Comprehensive analysis of m6A related gene mutation characteristics and prognosis in colorectal cancer

10.6084/m9.figshare.22877508.v1figshare

Additional file 3 of Comprehensive analysis of m6A related gene mutation characteristics and prognosis in colorectal cancer

10.6084/m9.figshare.22877508figshare

Additional file 4 of Comprehensive analysis of m6A related gene mutation characteristics and prognosis in colorectal cancer

10.6084/m9.figshare.22877511.v1figshare

Additional file 4 of Comprehensive analysis of m6A related gene mutation characteristics and prognosis in colorectal cancer

10.6084/m9.figshare.22877511figshare

Additional file 5 of Comprehensive analysis of m6A related gene mutation characteristics and prognosis in colorectal cancer

10.6084/m9.figshare.22877514.v1figshare

Additional file 5 of Comprehensive analysis of m6A related gene mutation characteristics and prognosis in colorectal cancer

10.6084/m9.figshare.22877514figshare

Additional file 6 of Comprehensive analysis of m6A related gene mutation characteristics and prognosis in colorectal cancer

10.6084/m9.figshare.22877517.v1figshare

Additional file 6 of Comprehensive analysis of m6A related gene mutation characteristics and prognosis in colorectal cancer

10.6084/m9.figshare.22877517figshare

Additional file 7 of Comprehensive analysis of m6A related gene mutation characteristics and prognosis in colorectal cancer

10.6084/m9.figshare.22877520.v1figshare

Additional file 7 of Comprehensive analysis of m6A related gene mutation characteristics and prognosis in colorectal cancer

10.6084/m9.figshare.22877520figshare

Additional file 8 of Comprehensive analysis of m6A related gene mutation characteristics and prognosis in colorectal cancer

10.6084/m9.figshare.22877523.v1figshare

Additional file 8 of Comprehensive analysis of m6A related gene mutation characteristics and prognosis in colorectal cancer

10.6084/m9.figshare.22877523figshare

Additional file 9 of Comprehensive analysis of m6A related gene mutation characteristics and prognosis in colorectal cancer

10.6084/m9.figshare.22877526.v1figshare

Additional file 9 of Comprehensive analysis of m6A related gene mutation characteristics and prognosis in colorectal cancer

10.6084/m9.figshare.22877526figshare

Additional file 1 of KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination

10.6084/m9.figshare.26027462.v1figshare

Additional file 1 of KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination

10.6084/m9.figshare.26027462figshare

Related Papers (10)

Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer

BMC Cancer(2021)

OpenAlex related

10.1186/s12885-021-07884-8

KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition

Cancer Research(2024)

OpenAlex related

10.1158/0008-5472.can-23-2709

Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway

Oncotarget(2015)

OpenAlex related

10.18632/oncotarget.3552

Assessing the significance of KRAS G12C mutation: Clinicopathologic features, treatments, and survival outcomes in a real-world KRAS mutant non-small cell lung cancer cohort.

Journal of Clinical Oncology(2020)

OpenAlex related

10.1200/jco.2020.38.15_suppl.e19324

Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer

Research Square(2020)

OpenAlex related

10.21203/rs.3.rs-108171/v1

DETERMINING QUALITY REQUIREMENTS AT THE UNIVERSITIES TO IMPROVE THE QUALITY OF EDUCATION

The Journal of Economic Research & Business Administration(2018)

OpenAlex related

10.26577/be-2018-2-2141

KRAS gene amplification to define a distinct molecular subgroup of gastroesophageal adenocarcinoma.

Journal of Clinical Oncology(2016)

OpenAlex related

10.1200/jco.2016.34.15_suppl.4065

Lung Cancer and KRAS -Its Molecular Biology/Genetics and Therapeutic Strategy-

Haigan(2022)

OpenAlex related

10.2482/haigan.62.188

127P RAS, RAF and NF1 oncogenic mutations in KRAS-mutated lung adenocarcinoma

Annals of Oncology(2022)

OpenAlex related

10.1016/j.annonc.2022.09.128

Abstract A004: KRAS allelic imbalance drives an epithelial MAPK-dependent tumor initiation program that is inefficient in provoking metastasis in colorectal cancer in vivo

Molecular Cancer Research(2023)

OpenAlex related

10.1158/1557-3125.ras23-a004

Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients

FAIR Checklist

Authors (3)

Funding (15 grants)

Impact

Open Access

Topics

Linked Datasets (20)

Annotations (Europe PMC)

Related Papers (10)